Get the Stockscreener App
1.77
4.84%
-0.09
After Hours:
1.70
-0.07
-3.95%
Cellectar Biosciences Inc stock is traded at $1.77, with a volume of 1.35M.
It is down -4.84% in the last 24 hours and down -15.31% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
See More
Previous Close:
$1.86
Open:
$1.85
24h Volume:
1.35M
Relative Volume:
5.07
Market Cap:
$74.63M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.5331
EPS:
-3.32
Net Cash Flow:
$-30.91M
1W Performance:
-16.51%
1M Performance:
-15.31%
6M Performance:
-46.36%
1Y Performance:
-14.90%
1-Day Range:
$1.66
$1.9499
1-Week Range:
$1.66
$2.18
52-Week Range:
$1.66
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CLRB | 1.77 | 74.63M | 0 | -37.75M | -30.91M | -3.32 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cellectar corrects accounting firm consent in SEC filing By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Update - MarketBeat
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - The Bakersfield Californian
Cellectar Reports Positive Phase 2 Results, Secures $19.4M in Warrant Exercises | CLRB Stock News - StockTitan
SEC Form 10-Q filed by Cellectar Biosciences Inc. - Quantisnow
Cellectar Biosciences (CLRB) Scheduled to Post Earnings on Monday - Defense World
Cellectar Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
ADAR1 Capital Management, LLC Expands Stake in Cellectar Bioscie - GuruFocus.com
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - GlobeNewswire
Cellectar Partners With NorthStar For Ac-225 Supply - Contract Pharma
Cellectar secures Ac-225 supply for cancer drug development - Investing.com
Cellectar Secures 10-Year Supply of Rare Cancer Treatment Isotope for Clinical Trials | CLRB Stock News - StockTitan
Cellectar Biosciences and SpectronRx Partner to Manufacture - GlobeNewswire
Cellectar Biosciences (CLRB) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - The Manila Times
CLRB (Cellectar Biosciences) 3-Year EBITDA Growth Rate : 25.40% (As of Jun. 2024) - GuruFocus.com
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 - The Manila Times
Cellectar Biosciences to Report Third Quarter Financial - GlobeNewswire
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 - GlobeNewswire
Cellectar's Breakthrough WM Cancer Drug Data Set for Major ASH 2024 Presentation | CLRB Stock News - StockTitan
Rosalind Advisors Inc. Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - MarketBeat
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q - GlobeNewswire
Sequoia Financial Advisors LLC Purchases New Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Current and Future Analysis of Neuroblastoma Therapeutic - openPR
Waldenstrom Macroglobulinemia Market to Show Remarkable - openPR
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Sees Large Increase in Short Interest - MarketBeat
Bone Cancer Drugs Market Next-Generation Dynamic Growth - openPR
Cellectar Biosciences (NASDAQ:CLRB) Receives Outperform Rating from Oppenheimer - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Given Outperform Rating at Oppenheimer - MarketBeat
Oppenheimer maintains Outperform rating on Cellectar Biosciences By Investing.com - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Shares Cross Above Fifty Day Moving Average – Here’s Why - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Stock Passes Above 50 Day Moving AverageTime to Sell? - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - GlobeNewswire
XTX Topco Ltd Purchases 51,413 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Upgraded at StockNews.com - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Upgraded to "Sell" by StockNews.com - MarketBeat
Cellectar Biosciences (NASDAQ:CLRB) Stock Quotes, Forecast and News Summary - Benzinga
Was there any good news for Cellebrite DI Ltd (CLBT) stock in the last session? - US Post News
Trust Investment Advisors Acquires Shares of 24,250 Celestica Inc. (NYSE:CLS) - MarketBeat
Cellucare Reviews (DO NOT BUY YET) Any Side Effects or Customer Complaints in 2024? - Businessday
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
CLS’s Stock Journey: What Investors Need to Know About Celestica, Inc.’s Performance - The InvestChronicle
Ratios Revealed: Decoding Celestica, Inc. (CLS)’s Financial Health - The Dwinnex
Celestica, Inc. (CLS) presents a great opportunity, but the stock is slightly undervalued - US Post News
Cellecor Gadgets Limted acquires 100% equity of Cellecor Foundation towards its CSR initiatives and commitments - APN News
Cellecor Gadgets shares rally 5% to hit new 52-week high; check key trigger - ET Now
Renaissance Technologies LLC Sells 12,126 Shares of Chemed Co. (NYSE:CHE) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com - Defense World
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):